Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Blood

Volumn 128, Issue 26, 2016, Pages 3113-3124

  Fucikova, Jitka ^a,b   Truxova, Iva ^a,b   Hensler, Michal ^b   Becht, Etienne ^c,d,e   Kasikova, Lenka ^a,b   Moserova, Irena ^a,b   Vosahlikova, Sarka ^b   Klouckova, Jana ^f   Church, Sarah E ^c,d,e   Cremer, Isabelle ^c,d,e   Kepp, Oliver ^c,d,e,g   Kroemer, Guido ^c,d,e,g,h,i   Galluzzi, Lorenzo ^c,d,e,g,j   Salek, Cyril ^k,l   Spisek, Radek ^a,b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Sotio   (Czech Republic)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CHARLES UNIVERSITY   (Czech Republic)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^l CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CD33 ANTIGEN; DAUNORUBICIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IDARUBICIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LEUKEMIA ANTIGEN; ALARMIN; CALRETICULIN, HUMAN;

ACUTE MYELOID LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CLINICAL OUTCOME; CYTOTOXICITY; DAMAGE ASSOCIATED MOLECULAR PATTERN; EXPOSURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL; BLAST CELL CRISIS; CELL DEATH; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; TH1 CELL; TREATMENT OUTCOME;

ALARMINS; BLAST CRISIS; CALRETICULIN; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; TH1 CELLS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 85015063326     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-731737     Document Type: Article

References (40)

1. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128-1138.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
3. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
4. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690-714.
5. Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol. 2015;59(1-3):131-140.
6. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
7. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860-875.
8. Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev. 2013;24(4):319-333.
9. Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 2011;71(14):4821-4833.
10. Fucikova J, Moserova I, Truxova I, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135(5):1165-1177.
11. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology. 2014;3:e28518.
12. Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187. doi:10.3389/fimmu.2015.00187.
13. Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi:10.3389/fimmu.2015.00588.
14. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445-474.
15. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109(11):4839-4845.
16. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94.
17. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573-1577.
18. Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972-978.
19. Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301-1309.
20. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. 2014;14(11):759-767.
21. Fucikova J, Moserova I, Urbanova L, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol. 2015;6:402. doi:10.3389/fimmu.2015.00402.
22. Fucikova J, Becht E, Iribarren K, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 2016;76(7):1746-1756.
23. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann Oncol. 2005; 16(2):314-321.
24. Peng RQ, Chen YB, Ding Y, et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol. 2010;16(19):2428-2434.
25. Vaksman O, Davidson B, Tropé C, Reich R. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol. 2013;44(12):2677-2683.
26. Wemeau M, Kepp O, TesnièreA,etal. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104.
27. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology. 2014;3(9):e955691.
28. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov. 2011;10(3):221-237.
29. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. Nat Cell Biol. 2014;16(8):728-736.
30. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood. 2006; 108(13):4109-4117.
31. Zhang L, Greiner J. Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia. Immunotherapy. 2011;3(6):697-699.
32. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012;26(10):2186-2196.
33. Garg AD, Elsen S, Krysko DV, Vandenabeele P, de Witte P, Agostinis P. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget. 2015;6(29):26841-26860.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
35. Elsner L, Flügge PF, Lozano J, et al. The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells. J Cell Mol Med. 2010;14(4):992-1002.
36. Stringaris K, Sekine T, Khoder A, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836-847.
37. Erić A, Juranić Z, Milovanović Z, et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res. 2009;15(1):89-90.
38. Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012;72(16):3967-3976.
39. Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? Expert Rev Hematol. 2016;9(4):335-350.
40. Grimwade D, Hills RK, Moorman AV, et al, National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.